Combating Viral Resistance to Treatment: VIRGIL After two Successful Years

Abstract

Future VirologyVol. 1, No. 5 Conference SceneCombating viral resistance to treatment: VIRGIL after two successful yearsJenny BryanJenny BryanFreelance Medical Journalist, London, UK. Search for more papers by this authorEmail the corresponding author at jennylbryan@aol.comPublished Online:19 Sep 2006https://doi.org/10.2217/17460794.1.5.567AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleBibliography1 Lai CL, Dienstag J, Schiff E et al.: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis.36(6),687–696 (2003).Crossref, Medline, CAS, Google Scholar2 Berg T, von Wagner M, Nasser S et al.: Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-α-2a plus ribavirin. Gastroenterology130(4),1086–1097 (2006).Crossref, Medline, CAS, Google Scholar3 Gross J, Johnson S, Kwo P et al.: Double-dose peginterferon α-2b with weight-based ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: final results of “RENEW”. Hepatology42(Suppl. 1),A60 (2005).Google Scholar4 Wakita T, Pietschmann T, Kato T et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med.11(7),791–796 (2005).Crossref, Medline, CAS, Google Scholar5 de Jong MD, Tran TT, Truong HK et al.: Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med.353(25),2667–2672 (2005).Crossref, Medline, CAS, Google Scholar6 Mishin VP, Hayden FG, Gubareva LV: Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother.49(11),4515–4520 (2005).Crossref, Medline, CAS, Google Scholar7 Marjuki H, Alam MI, Ehrhardt C et al.: Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase C-α-mediated activation of ERK signaling. J. Biol. Chem.281(24),16707–16715 (2006).Crossref, Medline, CAS, Google Scholar8 Charpentier C, Nora T, Tenaillon O et al.: Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J. Virol.80(5),2472–2482 (2006).Crossref, Medline, CAS, Google Scholar9 Oette M, Kaiser R, Daumer M et al.: Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J. Acquir. Immune Defic. Syndr.41(5),573–581 (2006).Crossref, Medline, Google Scholar10 Richman DD, Morton SC, Wrin T et al.: The prevalence of antiretroviral drug resistance in the United States. AIDS18,1393–1401 (2004).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 1, No. 5 Follow us on social media for the latest updates Metrics Downloaded 36 times History Published online 19 September 2006 Published in print September 2006 Information© Future Medicine LtdPDF download